# A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Source: https://onco.cc/trials/nct05951959/  
OnCo record `nct05951959` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib, Venetoclax, Rituximab in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05951959 by AstraZeneca, with 108 participants enrolled, started 2023-12-13 and due to reach its primary completion in 2028-10-31. Interventions recorded: Acalabrutinib, Venetoclax, Rituximab. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05951959
- Phase: 2
- Setting: A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
- Sponsor: AstraZeneca
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT05951959: https://clinicaltrials.gov/study/NCT05951959

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05951959.json